GEMZAR

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare GEMZAR to:

Generic Name for GEMZAR

Gemcitabine HCl 200mg, 1g; per vial; pwd for IV infusion after reconstitution; contains mannitol.

Legal Classification:

Pharmacological Class for GEMZAR

Antimetabolite.

Manufacturer of GEMZAR

Lilly, Eli and Company

Indications for GEMZAR

Advanced ovarian cancer (in combination with carboplatin) that has relapsed at least 6 months after completion of platinum-based therapy.

Other Indications for GEMZAR

Breast cancer

Pancreatic, thyroid, and other endocrine cancers

Respiratory and thoracic cancers

Adult dose for GEMZAR

Infuse over 30 minutes (increased toxicity if infusion goes beyond 60 minutes). 1000mg/m² on Days 1 and 8 of each 21 day cycle. Adjust dose based on toxicity (see literature).

Children's dosing for GEMZAR

Not recommended.

Warnings/Precautions for GEMZAR

Discontinue immediately if severe lung toxicity or hemolytic uremic syndrome occurs. Renal or hepatic impairment. Evaluate renal and hepatic function prior to therapy, then periodically thereafter. Monitor for myelosuppression; obtain CBCs, platelets prior to each dose. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended.

Adverse Reactions for GEMZAR

Myelosuppression, GI upset, elevated transaminases, proteinuria, hematuria, rash, pruritus, dyspnea, edema, flu-like symptoms, infection, alopecia, neurotoxicity, others; rare: renal or liver failure, hemolytic uremic syndrome.

Notes for GEMZAR

Testing considerations: ERCC1 overexpression for response and prognosis; RRM1

How is GEMZAR supplied?

Single-use vials—1

Related Disease:

Cancer, breast

Cancer, ovarian

Cancer, pancreatic

Non-small cell lung cancer

Data provided by the Monthly Prescribing Reference (MPR) Hematology/Oncology Edition.

Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer

May 18, 2012

Patients with gastric cancer who undergo resection show survival benefit 10 years later.

Fertility-Related Information Urgently Needed for Female Patients with Cancer

Debra Hughes May 18, 2012

Young adult males and females with cancer receive vastly different amounts of fertility-related and fertility preservation information.

STAT3 Mutations ID'd in Rare Lymphoproliferative Disorder

May 18, 2012

Four specific mutations in SH2 domain seen in T-cell large granular lymphocytic leukemia.

Genetic Profiling Improves Prognosis of Uveal Melanoma

James Netterwald, PhD May 18, 2012

Gene expression profiling (GEP) and chromosomal analysis show prognostic value in patients with uveal melanoma.

Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma

May 18, 2012

Zoledronate superior to placebo or etidronate for improving overall survival.

ADRIAMYCIN SOLUTION

Oncology > Bone and connective tissue cancer

Doxorubicin HCl 2mg/mL; soln for IV inj.

ARIMIDEX

Oncology > Breast cancer

Anastrozole 1mg; tabs.

CAMPATH

Oncology > Leukemias, lymphomas, and other hematologic cancers

Alemtuzumab 30mg/mL; soln; for IV infusion after dilution; preservative-free.

INTRON A SOLN

Oncology > Kaposi's sarcoma

Interferon alfa-2b, recombinant; 10million IU, 18million IU, 25million IU; per vial; for inj; contains m-cresol.

Mitomycin

Oncology > Pancreatic, thyroid, and other endocrine cancers

Mitomycin 5mg/vial, 20mg/vial, 40mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol.

Oncology > Cytoprotective and supportive care agents

Bisphosphonates (eg, Aredia, Zometa) may inhibit the activation of cancer-associated proteins through the suppression of geranyl-geranylation and farnesylation or inhibit ...
more »

'Teachable Moments' for Smoking Cessation in Patients Diagnosed with Cancer Underutilized

Debra Hughes February 16, 2012

Less than one-fifth (18.1%) of healthcare providers reported high levels of confidence in their ability to counsel patients with cancer who smoke to quit smoking, a survey published in The Oncologist online February 14 has found.